Metsera, Inc. Common Stock (MTSR) - Total Liabilities
Based on the latest financial reports, Metsera, Inc. Common Stock (MTSR) has total liabilities worth $190.43 Million USD as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Metsera, Inc. Common Stock - Total Liabilities Trend (2022–2024)
This chart illustrates how Metsera, Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data. See working capital position of Metsera, Inc. Common Stock to evaluate short-term liquidity relative to the company's equity base.
Metsera, Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of Metsera, Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
China National Software & Service Co Ltd
SHG:600536
|
China | CN¥4.74 Billion |
|
China Film Co Ltd
SHG:600977
|
China | CN¥8.66 Billion |
|
Bread Financial Holdings, Inc.
NYSE:BFH
|
USA | $18.98 Billion |
|
Nordstrom Inc
NYSE:JWN
|
USA | $7.83 Billion |
|
Godrej Industries Limited
NSE:GODREJIND
|
India | Rs1.03 Trillion |
|
Scorpio Tankers Inc
NYSE:STNG
|
USA | $666.02 Million |
|
Ultra Clean Holdings Inc
NASDAQ:UCTT
|
USA | $1.15 Billion |
|
Adata Technology Co Ltd
TWO:3260
|
Taiwan | NT$35.06 Billion |
Liability Composition Analysis (2022–2024)
This chart breaks down Metsera, Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of Metsera, Inc. Common Stock.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.26 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.42 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.30 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Metsera, Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Metsera, Inc. Common Stock (2022–2024)
The table below shows the annual total liabilities of Metsera, Inc. Common Stock from 2022 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $163.64 Million | +132.64% |
| 2023-12-31 | $70.34 Million | +345.39% |
| 2022-12-31 | $15.79 Million | -- |
About Metsera, Inc. Common Stock
Metsera, Inc., a clinical-stage biotechnology company, develops injectable and oral nutrient stimulated hormone analog peptides to treat obesity, overweight, and related diseases. It develops MET-097i and MET-233i for the treatment of obesity and overweight; MET-233i/MET-097i; and MET-002, MET-224o, MET-067i, and MET-034i to treat disorders, such as diabetes and obesity, as well as MET-815i to re… Read more